The liver in cystric fibrosis;Foie et mucoviscidose

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 8-9, 1997, Pages 607-618

  Lacaille, Florence ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cystic fibrosis; Diagnosis; Liver; Treatment; Ursodeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID;

ARTICLE; BILE DUCT DISEASE; CYSTIC FIBROSIS; FATTY LIVER; GALLBLADDER DISEASE; GENE THERAPY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; SCLEROSING CHOLANGITIS;

ADOLESCENT; ADULT; BILE DUCT DISEASES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GALLBLADDER DISEASES; HUMANS; INFANT; INFANT, NEWBORN; LIVER DISEASES; MALE;

EID: 0030886308     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis : current survival and population estimates to the year 2000. Thorax 1991;46:881-5.
2. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
3. Collins F. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-9.
4. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993;105:1857-64.
5. Férec C, Mercier B, Audrézet MP. Les mutations de la mucoviscidose: du génotype au phénotype. Médecine-Sciences 1994;10:631-9.
6. The Cystic Fibrosis Genetic Analysis Consortium. Worldwide survey of the ΔF508 mutation: report from the Cystic Fibrosis Genetic Analysis Consortium. Am J Hum Genet 1990;47:354-9.
7. Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992;50:1178-84.
8. The Cystic Fibrosis Genetic Analysis Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329:1308-13.
9. Waters DL, Dorney SFA, Gruca MA, Martin HCO, Howman-Giles R, Kan AE, et al. Hepatobiliary disease in cystic fibrosis patients with pancreatic sufficiency. Hepatology 1995;21:963-9.
10. Duthie A, Doherty DG, Williams C, Scott-Jupp R, Warner JO, Tanner MS, et al. Genotype analysis for ΔF508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease. Hepatology 1992;15:660-4.
11. De Arce M, O'Brien S, Hegarty J, Mahoney SM, Cashman SH, Martinez A, et al. Deletion ΔF508 and clinical expression of cystic fibrosis-related liver disease. Clin Genet 1992;42:271-2.
12. Colombo C, Apostolo MG, Ferrari M, Seia M, Genoni S, Giunta A, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994;124:393-9.
13. Andersen D. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938;56:344-99.
14. Bodian M. Fibrocystic disease of the pancreas. A congenital disorder of mucus production. London: William Heinemann Medical Books, 1952.
15. Di Sant'Agnese P, Blanc WA. Distinctive type of biliary cirrhosis of the liver associated with cystic fibrosis of the pancreas. Pediatrics 1956;18:387-409.
16. Stern RC, Stevens DP, Boat TF, Doershuk CF, Izant RJ, Matthews LW. Symptomatic hepatic disease in cystic fibrosis. incidence, course, and outcome of portal systemic shunting. Gastroenterology 1976;70:645-9.
17. Schuster SR, Shwachman H, Toyama WM, Rubino A, Taik-Khaw K. The management of portal hypertension in cystic fibrosis. J Pediatr Surg 1977;12:201-6.
18. Shwachman H, Kowalski M, Khaw KT. Cystic fibrosis: a new outlook. 70 patients above 25 years of age. Medicine 1977;56:129-49.
19. Park RW, Grand RJ. Gastrointestinal manifestations of cystic fibrosis: a review. Gastroenterology 1981;81:1143-61.
20. Psacharopoulos HT, Howard ER, Portmann B, Mowat AP, Williams R. Hepatic complications of cystic fibrosis. Lancet 1981;2:78-80.
21. Roy CC, Weber AM, Morin CL, Lepage G, Brisson G, Yousef I, et al. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr 1982;1:469-78.
22. Isenberg JN. Cystic fibrosis: its influence on the liver, biliary tree, and bile salt metabolism. Semin Liver Dis 1982;2:302-13.
23. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991;66:698-701.
24. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis. Therapeutic implications and long term follow up. Arch Dis Child 1993;68:653-7
25. Colombo C, Battezati PM, Podda M. Hepatobiliary disease in cystic fibrosis. Semin Liver Dis 1994;14:259-69.
26. Lenaerts C, Piussan C, Mathieu M, Pautard JC, Soto B, Munck A, et al. Cirrhosis and DF508 mutation in cystic fibrosis diagnosed during childhood. Proceedings of the 19th European Cystic Fibrosis Conference. Paris: European Cystic Fibrosis Association, 1994:182.
27. Williams SGJ, Hayllar K, Hudson ME, Westaby D. Prognosis in cystic fibrosis. N Engl J Med 1992;325:1244-5.
28. Farber S. Pancreatic funtion and disease in early life. V. Pathological changes associated with pancreatic insufficiency in early life. Arch Pathol 1944;37:238-50.
29. Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975;86:683-9.
30. Dietzsch HJ, Gollschalk B, Hinkel GK, Roschlau G. The value of bioptic follow-up examinations for controlling the course of liver involvement in cystic fibrosis. Proceedings of the 8th International Congress on Cystic Fibrosis. Toronto: Canadian CF Foundation, 1980:220-5.
31. Lindblad A, Hulterantz R, Strandvik B. Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 1992;16:372-81.
32. Maurage C, Lenaerts C, Weber A, Brochu P, Yousef I, Roy CC. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989;9:17-20.
33. Wilroy RS, Crawford SE, Johnson WW. Cystic fibrosis with extensive fat replacement of the liver. J Pediatr 1966;68:67-73.
34. Hultcrantz R, Mengarelli S, Strandvik B. Morphological findings in the liver of children with cystic fibrosis: a light and electron microscopical study. Hepatology 1986;6:881-9.
35. Lacaille F, Paradis K, Brochu P, Rasquin-Weber A. Who is the patient al risk for cirrhosis in cystic fibrosis ? The role of liver biopsy (abstract). Gastroenterology 1992:102;A838.
36. Lepage G, Levy E, Ronco N, Smith L, Galéano N, Roy CC. Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis. J Lipid Res 1989;30:1483-90.
37. Dray-Charier N, Paul A, Veissière D, Mergey M, Scoazec JY, Capeau J, et al. The cystic fibrosis transmembrane conductance regulator gene is expressed in human gallbladder epithelial cells (abstract). Hepatology 1994;20:259A.
38. Roberts SK, Ludwig J, LaRusso NF. The pathobiology of biliary epithelia. Gastroenterology 1997;112:269-79.
39. Fitz JG, Basavappa S, McGill J, Melhus O, Cohn JA. Regulation of membrane chloride currents in rat bile duct epithelial cells. J Clin Invest 1993;91:319-28.
40. Nathanson MH, Boyer JL. Mechanisms and regulation of bile secretion. Hepalology 1991;14:551-66.
41. MePherson MA, Dormer RI. Cystic fibrosis and mucin secretion. Lancet 1994;343:7.
42. Weber AM, Roy CC, Morin CL, Lasalle R. Malabsorption of bile acids in children with cystic fibrosis. N Engl J Med 1973;289:1001-5.
43. Colombo C, Roda A, Roda R, Piceni Sereni L, Brega A, Fugazza R, et al. Bile acid malabsorption in cystic fibrosis with and without pancreatic insufficiency. J Pediatr Gastroenterol Nutr 1984;3:556-62.
44. O'Brien S, Mulcahy H, Fenlon H, O'Broin A, Casey M, Burke A, et al. Intestinal bile acid malabsorption in cystic fibrosis. Gut 1993;34:1137-41.
45. Nakagawa M, Colombo C, Setchell KD. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 1990;12:322-34.
46. Schölmerich J, Becher MS, Schmidt K, Schubert R, Kremer B, Felhaus S, et al. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties. Studies on isolated hepatocytes and lipid membrane vesicles. Hepatology 1984;4:661-6.
47. Bass S, Connon JJ, Ho CS. Biliary tree in cystic fibrosis. Biliary tract abnormalities in cystic fibrosis demonstrated by endoscopic retrograde cholangiography. Gastroenterology 1983;84:1592-6.
48. Gaskin KJ, Waters DLM, Howman-Giles R, De Silva M, Earl JW, Martin HCO, et al. Liver disease and common-bile-duct stenosis in cystic fibrosis. N Engl J Med 1988;318:340-6.
49. Strandvik B, Hjelte L, Gabrielsson N, Glaumann H. Sclerosing cholangitis in cystic fibrosis. Scand J Gastroenterol 1988;23 (suppl 143):121-4.
50. O'Brien S, Keogan M, Casey M, Duffy G, McErlean D, FitzGerald MX, et al. Biliary complications of cystic fibrosis. Gut 1992;33:387-91.
51. Valman H, France N, Wallis P. Prolonged neonatal jaundice in cystic fibrosis. Arch Dis Child 1971;46:805-9.
52. Holsclaw DS, Eckstein HB, Nixon HH. Meconium ileus. Am J Dis Child 1965;109:101-13.
53. Donnison AB, Shwachman H, Gross RE. A review of 164 children with meconium ileus seen at the Children's Hospital Medical Center, Boston. Pediatrics 1966;37:833-50.
54. Bernard O. Plaidoyer pour le diagnostic précoce de l'atrésie des voies biliaires. Douze erreurs à ne pas commettre. Arch Pediatr 1995;2:937-9.
55. Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996;75:67-70.
56. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1,2 million babies. J Pediatr 1995;127:965-70.
57. Mieles LA, Orenstein D, Teperman L, Podesta L, Koneru B, Starzl TE. Liver transplantation in cystic fibrosis. Lancet 1989;1:1073.
58. Rosenstein BJ, Oppenheimer EH. Prolonged obstructive jaundice and giant cell hepatitis in an infant with cystic fibrosis. J Pediatr 1977;91:1022-3.
59. Furuya KN, Roberts EA, Canny GJ, Phillips MJ. Neonatal hepatitis sydrome with paucity of interlobular bile ducts in cystic fibrosis. J Pediatr Gastroenterol Nutr 1991;12:127-30.
60. Evans JS, George DE, Mollit D. Biliary infusion therapy in the inspissated bile syndrome of cystic fibrosis. J Pediatr Gastroenterol Nutr 1991;12:131-5.
61. Balistreri WF. Neonatal cholestasis. J Pediatr 1985;106:171-83.
62. Rosenstein BJ, Langbaum TS. Incidence of distal intestinal obstruction syndrome in cystic fibrosis. J Pediatr Gastroenterol Nutr 1983;2:299-301.
63. Nagel RA, Westaby D, Javaid A, Kavani J, Meire HB, Lombard MG, et al. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989;2:1422-5.
64. Lindblad A, Strandvik B, Hjelte L. Incidence of liver disease in patients with cystic fibrosis and meconium ileus. J Pediatr 1995;126:155-6.
65. Wilson-Sharp RC, Irving HC, Brown RC, Chalmers DM, Littlewood JM. Ultrasonography of the pancreas, liver and biliary system in cystic fibrosis. Arch Dis Child 1984;59:923-6.
66. ére partie). Gastroenterol Clin Biol 1995;19:58-65.
67. Di Sant'Agnese, Davis PB. Cystic fibrosis in adults: 75 cases and a review of 232 cases in the litterature. Am J Med 1979;66:121-32.
68. Stern RC, Rothstein FC, Doershuk CF. Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1986;5:35-40.
69. Angelico M, Gandin C, Canuzzi P, Bertasi S, Cantafora A, De Santis A, et al. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology 1991;14:768-75.
70. Roy CC, Weber AM, Morin CL, Combes JC, Nusslé D, Mégevand A, et al. Abnormal biliary lipid composition in cystic fibrosis. N Engl J Med 1977;297:1301-5.
71. Colombo C, Bertolini E, Assaisso ML, Bettinardi N, Giunta A, Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993;82:562-5.
72. Décarie JC, Garel L, Lacaille F. Multiple intra-hepatic stones in cystic fibrosis: a case report (abstract). Pediatr Radiol 1990;20:412.
73. Greuves RRSH, Patchett SE, Empey SE, Kumar PJ. Case report: a 22-year-old with jaundice and a bit of a cough. Lancet 1997;349:324.
74. Terada T, Nakanuma Y. Intrahepatic cholangiographic appearance simulating primary sclerosing cholangitis in several hepatobiliary diseases: a postmortem cholangiographic and histopathological study in 154 livers at autopsy. Hepatology 1995;22:75-81.
75. Abdul-Karim FW, King TA, Dahms BB, Gauderer MWL, Boat TF. Carcinoma of extrahepatic biliary system in an adult with cystic fibrosis. Gastroenterology 1982;82:758-62.
76. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaiso ML. Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992;15:677-84.
77. O'Connor PJ, Southern KW, Bowler IM, Irving HC, Robinson PJ, Littlewood JM. The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology 1996;23:281-7.
78. Roy CC, Lenaerts C, Garel L, Patriquin H, Weber AM. Biliary disease in cystic fibrosis. N Engl J Med 1988;319:312-3.
79. Stockberger SM, Wass JL, Sherman S, Lehman GA, Kopecky KK. Intravenous cholangiography with helical CT: comparison with endoscopic retrograde cholangiography. Radiology 1994;192:675-80.
80. Treem WR, Stanley CA. Massive hepatomegaly, steatosis, and secondary plasma carnitine deficiency in an infant with cystic fibrosis. Pediatrics 1989;83:993-7.
81. Lévy S, Capron JP, Erlinger S. Mécanisme d'action de l'acide ursodésoxycholique dans les maladies du foie cholestatiques. Gastroenterol Clin Biol 1996;20:549-59.
82. Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side-chain shortening on the physiological properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986;90:837-52.
83. Heumann DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993;104:1865-70.
84. Cutting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990;31:918-21.
85. Colombo C, Setchell KDR, Podda M, Crisignani A, Roda A, Curcio L, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990;117:482-9.
86. Galabert C, Montet JC, Lengrand D, Lecuire A, Sotta C, Figarella C, et al. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr 1992;121:138-41.
87. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A, and the Italian Group for the study of UDCA in cystic fibrosis. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 1996;23:1484-90.
88. Colombo C, Crosignani A, Assaisso ML, Batlezzati PM, Podda M, Giunta A, et al. Ursodeoxycholic acid therapy in cystic fibrosis-related liver disease: a dose-response study. Hepatology 1992;16:924-30.
89. Merli M, Bertasi S, Servi R, Diamanti S, Martino F, De Santis A, et al. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1994;19:198-203.
90. Thomas PS, Bellamy M, Geddes D. Malabsorption of vitamin E in cystic fibrosis improved after ursodeoxycholic acid. Lancet 1995;346:1230-1.
91. Smith LJ, Lacaille F, Lepage G, Ronco N, Lamarre A, Roy CC. Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. Am J Dis Child 1991;145:1401-4.
92. Beuers U, Spengler U, Ruis W, Aydemir W, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-14.
93. Noble-Jamicson G, Valente J, Barnes ND, Friend PJ, Jamieson NV, Rasmussen A, et al. Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child 1994;71:349-52.
94. Noble-Jamieson G, Barnes ND. Liver transplantation for cirrhosis in cystic fibrosis. J Pediatr 1996;129:314.
95. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-88.
96. Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993;18:477-84.
97. Ramond MJ. Techniques et indications du traitement endoscopique des varices œso-gastriques en 1995. Gastroenterol Clin Biol 1995;19:921-34.
98. Stringer MD, Price JF, Mowat AP, Howard ER. Liver cirrhosis in cystic fibrosis. Arch Dis Child 1993;69:407.
99. Richardson VF, Robertson CF, Mowat AP, Howard ER, Price JF. Deterioration in lung function after general anesthesia in patients with cystic fibrosis. Acta Paediatr Scand 1984;73:75-9.
100. Laine L, Stein C, Sharma V. Randomized comparison of ligation versus ligation plus sclerotherapy in patients with bleeding esophagal varices. Gastroenterology 1996;110:529-33.
101. Fox VL, Carr-Locke DL, Connors PJ, Leichtner AM. Endoscopic ligation of esophageal varices in children. J Pediatr Gastroenterol Nutr 1995;20:202-8.
102. Duché M, Lascar G, Cadet-Jérémie S, Bernard O. Ligature endoscopique des varices œso-gastriques chez l'enfant. Gastroenterol Clin Biol 1996;20:322-3.
103. Barange K, Rousseau H, Vinel JP. Anastomose porto-systémique intra-hépatique et traitement de l'hypertension portale. Gastroenterol Clin Biol 1996;20:674-88.
104. Goffette P, de Ville J, Reding R, Hammer F, Clapuyt P, Mathurin P, et al. Shunt porto-cave percutané par voie jugulaire chez l'enfant (résumé). Gastroenterol Clin Biol 1995;19:A216.
105. Berger KJ, Schreiber RA, Tchervenkov J, Kopelman H, Brassard R, Stein L. Decompression of portal hypertension in a child with cystic fibrosis after transjugular intrahepatic portosystemic shunt placement. J Pediatr Gastroenterol Nutr 1994;19:322-5.
106. Sanyal AJ, Freedman AM, Shiffman ML, Purdum III PP, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994;20:46-55.
107. Cadranel J, Cadranel JF. Désordres vasculaires pulmonaires au cours des maladies chroniques du foie. Gastroenterol Clin Biol 1994;18:824-8.
108. Barbé T, Losay J, Grimon G, Devictor D, Sardet A, Gauthier F, et al. Pulmonary arterio-venous shunting in children with liver disease. J Pediatr 1995;126:571-9.
109. Giniès JL, Couetil JP, Houssin D, Guillemain R, Champion G, Bernard O. Hepatopulmonary syndrome in a child with cystic fibrosis. J Pediatr Gastroenterol Nutr 1996;23:497-500.
110. Mathurin P, Mouquet C, Nguyen Khac E, Barrou B, Taïeb J, Bernard B, et al. La cirrhose est-elle une contre-indication à la transplantation rénale ? Etude rétrospective cas-témoin (résumé). Gastroenterol Clin Biol 1996;20:822.
111. Pol S, Garrigue V, Legendre C. Long term outcome of hepatitis C infection after renal transplantation. N Engl J Med 1996;335:522.
112. Cox KL, Ward RE, Furgiuele TL, Cannon RA, Sanders KD, Kurland G. Orthotopic liver transplantation in patients with cystic fibrosis. Pediatrics 1987;80:571-4.
113. Couetil JP, Houssin D, Soubrane O, Chevalier PG, Dousset BE, Loulmet D, et al. Combined lung and liver transplantation in patients with cystic fibrosis: a 4 1/2 year experience. J Thorac Cardiovasc Surg 1995;110:1415-23.
114. Mack DR, Traystman MD, Colombo JL, Sammut PH, Kaufman SS, Vanderhoof JA, et al. Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. J Pediatr 1995;127:881-7.
115. Gallery MP, Mangino MJ, Flye MW. Arginine-specific suppression of mixed lymphocyte culture reactivity by Kupffer cells. A basis of portal venous tolerance. Transplantation 1991;51:1076-80.
116. Yang Y, Raper SE, Cohn JA, Engelhardt JF, Wilson JM. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci USA 1993;90:4601-5.
117. Grubman SA, Fang SL, Mulberg AE, Perrone RD, Rogers LC, Lee DW, et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology 1995;108:584-92.